Injectable vs. Oral GLP-1: Which Format Wins in 2026?

Prices verified May 22, 2026 · Updated for 2026

2026 changed the oral GLP-1 landscape

Until December 2025, the only oral GLP-1 available was Rybelsus—approved for type 2 diabetes, not weight loss, and producing modest results compared to injectable options. Then two things happened in quick succession: the FDA approved the Wegovy pill (oral semaglutide 25mg) for weight loss in December 2025, and Foundayo (orforglipron), the first non-peptide oral GLP-1, received approval in April 2026.

For the first time, patients have a genuine choice between injection and pill. Here's how they compare.

The weight loss data

*Compounded semaglutide uses the same active ingredient as Wegovy but has not been independently studied in clinical trials. Results are assumed comparable at equivalent doses.

Convenience comparison

Foundayo's lack of food and water restrictions is a meaningful differentiator. The Wegovy pill requires strict fasting conditions—taken first thing in the morning with no more than 4 oz of plain water, then a 30-minute wait before eating or drinking anything else. Miss the timing, and absorption drops significantly. Foundayo has none of these constraints.

Pricing in 2026

The oral options have dramatically compressed pricing. Foundayo at $149/mo and the Wegovy pill starting at $149/mo are approaching compounded injectable territory—without the regulatory uncertainty of compounding.

Who should choose injectable

• Patients seeking maximum weight loss (14.9–20.9% vs 11–13.6%)
• Patients who prefer once-weekly dosing over daily pills
• Patients already successfully on injectable GLP-1s
• Patients wanting tirzepatide (injectable only for weight loss)
• Cash-pay patients seeking the lowest cost via compounded options

Who should choose oral

• Patients with needle phobia or aversion to self-injection
• Frequent travelers who need room-temperature storage
• Patients who want brand-name at an accessible price point ($149/mo)
• Patients stepping down from injectable after reaching their goal weight (Foundayo has data supporting this transition)
• Patients preferring the simplicity of a pill with no cold chain logistics

The compounded question

Compounded injectable semaglutide remains the most affordable option ($99–$299/mo), but the pricing gap has narrowed considerably with Foundayo at $149/mo and the Wegovy pill starting at $149/mo. For patients weighing the compounding regulatory risk against brand-name convenience, the oral options now present a viable middle path—FDA-approved, brand-name, and competitively priced.

That said, compounded injectables still deliver the strongest weight loss results at the lowest cost. For pure cost-per-pound-lost, compounded injectable semaglutide through a verified provider remains the market leader.

Our verdict

Injectable GLP-1s win on efficacy. Oral GLP-1s win on convenience. The right choice depends on whether you're optimizing for maximum weight loss or maximum ease of use. For most first-time patients in 2026, we'd recommend starting with an injectable through a verified compounded provider (best value) or trying the Wegovy pill if needles are a non-starter. Foundayo is the most convenient daily option but produces less weight loss than either semaglutide formulation.